麗新發展(00488.HK)供股獲超購約667.24%
格隆匯10月5日丨麗新發展(00488.HK)公吿,於2021年9月27日下午四時正,(a)已接獲合共216份涉及3.19億股根據供股暫定配發的供股股份的有效接納,佔供股項下可供認購供股股份總數3.23億股約98.65%;及(b)已接獲合共131份涉及21.59億股額外供股股份的有效申請,佔供股項下可供認購供股股份總數約668.59%。綜合計算,已接獲合共347份涉及24.78億股供股股份的有效接納及申請,佔供股項下可供認購供股股份總數約767.24%。
供股於2021年9月28日下午四時正成為無條件。由於供股股份已獲超額認購,故包銷商於包銷協議項下有關包銷股份的責任已經全面解除。預期供股股份將於2021年10月7日上午九時正以繳足股款方式於聯交所開始買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.